Logo image of INDV

INDIVIOR PLC (INDV) Stock Fundamental Analysis

NASDAQ:INDV - Nasdaq - GB00BN4HT335 - Common Stock - Currency: USD

8.45  -0.54 (-6.01%)

After market: 8.44 -0.01 (-0.12%)

Fundamental Rating

3

Overall INDV gets a fundamental rating of 3 out of 10. We evaluated INDV against 194 industry peers in the Pharmaceuticals industry. INDV has a medium profitability rating, but doesn't score so well on its financial health evaluation. INDV has a bad growth rate and is valued cheaply.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year INDV was profitable.
INDV had a negative operating cash flow in the past year.
In multiple years INDV reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: INDV reported negative operating cash flow in multiple years.
INDV Yearly Net Income VS EBIT VS OCF VS FCFINDV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

1.2 Ratios

With an excellent Return On Assets value of -0.14%, INDV belongs to the best of the industry, outperforming 81.62% of the companies in the same industry.
With an excellent Return On Invested Capital value of 47.37%, INDV belongs to the best of the industry, outperforming 98.92% of the companies in the same industry.
INDV had an Average Return On Invested Capital over the past 3 years of 24.06%. This is significantly below the industry average of 44.04%.
The 3 year average ROIC (24.06%) for INDV is below the current ROIC(47.37%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -0.14%
ROE N/A
ROIC 47.37%
ROA(3y)2.77%
ROA(5y)1.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)24.06%
ROIC(5y)19.44%
INDV Yearly ROA, ROE, ROICINDV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 200 300 400

1.3 Margins

INDV's Profit Margin has declined in the last couple of years.
The Operating Margin of INDV (25.44%) is better than 90.81% of its industry peers.
INDV's Operating Margin has declined in the last couple of years.
INDV's Gross Margin of 82.42% is amongst the best of the industry. INDV outperforms 88.65% of its industry peers.
In the last couple of years the Gross Margin of INDV has remained more or less at the same level.
Industry RankSector Rank
OM 25.44%
PM (TTM) N/A
GM 82.42%
OM growth 3Y22.01%
OM growth 5Y-5.65%
PM growth 3YN/A
PM growth 5Y-63.27%
GM growth 3Y-0.77%
GM growth 5Y-0.81%
INDV Yearly Profit, Operating, Gross MarginsINDV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60 80

More info and screens

2

2. Health

2.1 Basic Checks

INDV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, INDV has about the same amount of shares outstanding.
INDV has less shares outstanding than it did 5 years ago.
INDV has a better debt/assets ratio than last year.
INDV Yearly Shares OutstandingINDV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M
INDV Yearly Total Debt VS Total AssetsINDV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

INDV has an Altman-Z score of 1.56. This is a bad value and indicates that INDV is not financially healthy and even has some risk of bankruptcy.
INDV has a Altman-Z score of 1.56. This is in the better half of the industry: INDV outperforms 63.78% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 1.56
ROIC/WACC4.51
WACC10.5%
INDV Yearly LT Debt VS Equity VS FCFINDV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 0.83 indicates that INDV may have some problems paying its short term obligations.
INDV's Current ratio of 0.83 is on the low side compared to the rest of the industry. INDV is outperformed by 90.27% of its industry peers.
A Quick Ratio of 0.65 indicates that INDV may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.65, INDV is doing worse than 90.81% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.83
Quick Ratio 0.65
INDV Yearly Current Assets VS Current LiabilitesINDV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B

More info and screens

1

3. Growth

3.1 Past

The earnings per share for INDV have decreased strongly by -24.29% in the last year.
The earnings per share for INDV have been decreasing by -29.08% on average. This is quite bad
Looking at the last year, INDV shows a small growth in Revenue. The Revenue has grown by 4.34% in the last year.
The Revenue has been decreasing by -4.53% on average over the past years.
EPS 1Y (TTM)-24.29%
EPS 3Y-29.08%
EPS 5YN/A
EPS Q2Q%-25.58%
Revenue 1Y (TTM)4.34%
Revenue growth 3Y-4.53%
Revenue growth 5YN/A
Sales Q2Q%1.71%

3.2 Future

The Earnings Per Share is expected to decrease by -15.65% on average over the next years. This is quite bad
INDV is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -6.61% yearly.
EPS Next Y8.11%
EPS Next 2Y-1.39%
EPS Next 3Y-10.28%
EPS Next 5Y-15.65%
Revenue Next Year3.53%
Revenue Next 2Y-2.92%
Revenue Next 3Y-9.06%
Revenue Next 5Y-6.61%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
INDV Yearly Revenue VS EstimatesINDV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B
INDV Yearly EPS VS EstimatesINDV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0.5 1 1.5 2 2.5

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 4.83, which indicates a rather cheap valuation of INDV.
Compared to the rest of the industry, the Price/Earnings ratio of INDV indicates a rather cheap valuation: INDV is cheaper than 97.30% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of INDV to the average of the S&P500 Index (29.63), we can say INDV is valued rather cheaply.
INDV is valuated cheaply with a Price/Forward Earnings ratio of 4.97.
Compared to the rest of the industry, the Price/Forward Earnings ratio of INDV indicates a rather cheap valuation: INDV is cheaper than 95.68% of the companies listed in the same industry.
INDV's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.68.
Industry RankSector Rank
PE 4.83
Fwd PE 4.97
INDV Price Earnings VS Forward Price EarningsINDV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, INDV is valued cheaply inside the industry as 97.30% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 3.15
INDV Per share dataINDV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A cheap valuation may be justified as INDV's earnings are expected to decrease with -10.28% in the coming years.
PEG (NY)0.6
PEG (5Y)N/A
EPS Next 2Y-1.39%
EPS Next 3Y-10.28%

More info and screens

0

5. Dividend

5.1 Amount

INDV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INDIVIOR PLC

NASDAQ:INDV (2/21/2025, 8:00:01 PM)

After market: 8.44 -0.01 (-0.12%)

8.45

-0.54 (-6.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-20 2025-02-20/bmo
Earnings (Next)07-23 2025-07-23
Inst Owners89.83%
Inst Owner Change5.69%
Ins Owners3.68%
Ins Owner ChangeN/A
Market Cap1.05B
Analysts82.5
Price Target16.51 (95.38%)
Short Float %1.19%
Short Ratio1.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.7%
PT rev (3m)-14.12%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-2.41%
EPS NY rev (3m)-2.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.11%
Valuation
Industry RankSector Rank
PE 4.83
Fwd PE 4.97
P/S 0.89
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 3.15
EPS(TTM)1.75
EY20.71%
EPS(NY)1.7
Fwd EY20.14%
FCF(TTM)-2.2
FCFYN/A
OCF(TTM)-1.93
OCFYN/A
SpS9.53
BVpS-1.35
TBVpS-2.88
PEG (NY)0.6
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.14%
ROE N/A
ROCE 59.96%
ROIC 47.37%
ROICexc 129.23%
ROICexgc N/A
OM 25.44%
PM (TTM) N/A
GM 82.42%
FCFM N/A
ROA(3y)2.77%
ROA(5y)1.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)24.06%
ROIC(5y)19.44%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)30.46%
ROCE(5y)24.6%
ROICexcg growth 3Y164.05%
ROICexcg growth 5YN/A
ROICexc growth 3Y-1.7%
ROICexc growth 5YN/A
OM growth 3Y22.01%
OM growth 5Y-5.65%
PM growth 3YN/A
PM growth 5Y-63.27%
GM growth 3Y-0.77%
GM growth 5Y-0.81%
F-Score3
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0.81
Cap/Depr 100%
Cap/Sales 2.79%
Interest Coverage 9.12
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.83
Quick Ratio 0.65
Altman-Z 1.56
F-Score3
WACC10.5%
ROIC/WACC4.51
Cap/Depr(3y)124.13%
Cap/Depr(5y)82.56%
Cap/Sales(3y)3.27%
Cap/Sales(5y)2.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.29%
EPS 3Y-29.08%
EPS 5YN/A
EPS Q2Q%-25.58%
EPS Next Y8.11%
EPS Next 2Y-1.39%
EPS Next 3Y-10.28%
EPS Next 5Y-15.65%
Revenue 1Y (TTM)4.34%
Revenue growth 3Y-4.53%
Revenue growth 5YN/A
Sales Q2Q%1.71%
Revenue Next Year3.53%
Revenue Next 2Y-2.92%
Revenue Next 3Y-9.06%
Revenue Next 5Y-6.61%
EBIT growth 1Y27.54%
EBIT growth 3Y45.31%
EBIT growth 5Y-4.05%
EBIT Next Year10.57%
EBIT Next 3Y13.37%
EBIT Next 5Y10.71%
FCF growth 1Y-256%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-232.6%
OCF growth 3YN/A
OCF growth 5YN/A